ADMA Biologics Inc (ADMA): Price and Financial Metrics

ADMA Biologics Inc (ADMA)

Today's Latest Price: $2.37 USD

0.09 (-3.65%)

Updated Jan 27 9:14am

Add ADMA to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 484 in Biotech

See all "A" rated Strong Buy stocks

ADMA Stock Summary

  • With a price/sales ratio of 5.77, Adma Biologics Inc has a higher such ratio than 73.74% of stocks in our set.
  • Revenue growth over the past 12 months for Adma Biologics Inc comes in at 88.6%, a number that bests 93.94% of the US stocks we're tracking.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for ADMA comes in at -48.08% -- higher than that of merely 6.06% of stocks in our set.
  • Stocks that are quantitatively similar to ADMA, based on their financial statements, market capitalization, and price volatility, are CPST, NXTD, ENVA, SWM, and TTMI.
  • Visit ADMA's SEC page to see the company's official filings. To visit the company's web site, go to

ADMA Stock Price Chart Interactive Chart >

Price chart for ADMA

ADMA Price/Volume Stats

Current price $2.37 52-week high $4.25
Prev. close $2.46 52-week low $1.45
Day low $2.37 Volume 116,321
Day high $2.37 Avg. volume 3,792,654
50-day MA $2.08 Dividend yield N/A
200-day MA $2.53 Market Cap 224.08M

ADMA Biologics Inc (ADMA) Company Bio

ADMA Biologics, Inc. develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The company was founded in 2004 and is based in Ramsey, New Jersey.

ADMA Latest News Stream

Event/Time News Detail
Loading, please wait...

ADMA Latest Social Stream

Loading social stream, please wait...

View Full ADMA Social Stream

Latest ADMA News From Around the Web

Below are the latest news stories about Adma Biologics Inc that investors may wish to consider to help them evaluate ADMA as an investment opportunity.

ADMA Biologics: A Perfect Storm

ADMA Biologics, Inc. (ADMA) is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. I have been watching ADMA on the sidelines for several months but recently...

Jeffrey Himelson on Seeking Alpha | January 5, 2021

ADMA Biologics Receives Unique Temporary C-Code and Pass-Through Payment Status for ASCENIV™

RAMSEY, N.J. and BOCA RATON, Fla., Jan. 04, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that the Centers for Medicare and Medicaid Services (CMS) has approved transitional pass-through payment status and established a new reimbursement C-code, C9072, for ASCENIV which is effective January 1, 2021. “Assignment of this new C-code by CMS for ASCENIV, along with pass-through payment status, will provide a more streamlined reimbursement process in the increasingly important hospital outpatient setting,” said Adam Grossman, President and Chief Executive Officer of ADMA. “This is another significant milestone in our ongoi...

Yahoo | January 4, 2021

ADMA Biologics, Inc. (NASDAQ:ADMA) Insiders Increased Their Holdings

We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...

Yahoo | December 22, 2020

Is ADMA A Good Stock To Buy According To Hedge Funds?

After several tireless days we have finished crunching the numbers from nearly 817 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms’ equity portfolios as of September 30th. The results of that effort will be put on display in this article, as […]

Yahoo | December 19, 2020

ADMA Biologics Adopts Limited Duration Stockholder Rights Plan

RAMSEY, N.J. and BOCA RATON, Fla., Dec. 16, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that its Board of Directors has approved the adoption of a limited duration stockholder rights plan and declared a dividend distribution of one right for each outstanding share of common stock. The record date for such dividend distribution is December 30, 2020. The rights plan expires, without any further action being required to be taken by ADMA’s Board of Directors, on December 15, 2021. The adoption of the rights plan is intended to protect ADMA and its stockholders from the actions of third parties that ADMA’s Board of Dire...

Yahoo | December 16, 2020

Read More 'ADMA' Stories Here

ADMA Price Returns

1-mo 14.49%
3-mo 16.75%
6-mo -33.61%
1-year -42.20%
3-year -39.85%
5-year -60.70%
YTD 21.54%
2020 -51.25%
2019 67.36%
2018 -25.55%
2017 -37.30%
2016 -36.56%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9184 seconds.